ERBB2 and breast cancer: Our data support the phenomenon that CCA-1.1 performs onefold to twofold better cytotoxic activities on several cancer cells than PGV-1, which agrees with previous findings.1–3,30 In this regard, the two synthesized compounds were evaluated in vitro against some samples of breast cancer cell lines (MCF-7/HER2, 4T1, MCF-7, HCC1954, and T47D), human leukemic cells (K562), human colon carcinoma cells (Caco2 and WiDr), and immortalized fibroblast cells (NIH-3T3) as the reference of healthy cells.